Top Markets
Coin of the day
Invivyd, Inc. Invivyd, Inc.

Invivyd, Inc.

IVVD
Pozycja w akcjach #17262
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development... Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Cena akcji
$0.8799
Ostatnia synchronizacja: 2026-09-01
Kapitalizacja rynkowa
$259.22M
Zmiana (1 dzień)
-7.85%
Zmiana (1 rok)
-14.57%
Kraj
US
Handel Invivyd, Inc. (IVVD)

Kategoria

Historia stopy dywidendy dla Invivyd, Inc. (IVVD)
Stopa dywidendy (TTM) dla Invivyd, Inc. (symbol akcji: IVVD) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Invivyd, Inc. (IVVD) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji